Germany's BioNTech on Friday was awarded fast track designation by U.S. drugs regulators for the speedy review of a novel skin cancer therapy, which is based on RNA technology similar to the one that underpins its COVID-19 vaccine.
1 min read
FRANKFURT - Germany's BioNTech on Friday was awarded fast track designation by U.S. drugs regulators for the speedy review of a novel skin cancer therapy, which is based on RNA technology similar to the one that underpins its COVID-19 vaccine. The U.S. Food and Drug Administration granted the fast track status to the BNT111 infusion, which is designed to instruct the body to produce four proteins that are characteristic of melanoma cells and trigger an immune response against those cancer cells in the body.
Melanoma is a particularly deadly type of skin cancer when it has started spreading to other parts of the body, which is the setting in which BNT111 is currently being tested. Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA authorizes Pfizer/BioNTech and Moderna coronavirus vaccine boosters for all adultsThe US Food and Drug Administration on Friday authorized boosters of the Pfizer/BioNTech and Moderna Covid-19 vaccines for all adults.
Read more »
FDA authorizes Pfizer/BioNTech, Moderna COVID-19 boostersThe U.S. Food and Drug Administration on Friday authorized booster doses of COVID-19 vaccines for all adults who were vaccinated with the Pfizer Inc and partner BioNTech SE shot and the Moderna Inc shot.
Read more »
FDA OKs Pfizer, Moderna COVID-19 booster shot for all adultsInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
FDA authorizes Pfizer and Moderna boosters for all adultsBREAKING: FDA authorizes Pfizer and Moderna's Covid-19 boosters for all adults, a move that will make boosters available to everyone ages 18 and up.
Read more »
FDA authorizes Pfizer, Moderna boosters for all adults, sending process to CDC for last stepsBREAKING: The FDA has authorized booster doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 18 and older who is already considered fully vaccinated.
Read more »
FDA expected to approve Covid booster for all adultsAfter some confusion over booster eligibility, the FDA is expected to approve Covid booster shots for all adults nationwide. Dr. Kavita Patel tells Lawrence O’Donnell that the need for a booster doesn’t mean the vaccine wasn’t effective. “This is a novel virus, we’ve never had a vaccine for it before. And as we’re learning – like many other viruses – we need at least three doses to constitute full immunity for at least a year.”
Read more »